Acutaas Chemicals Ltd
NSE:ACUTAAS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Acutaas Chemicals Ltd
NSE:ACUTAAS
|
178.9B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
966.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.7B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
249.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.4B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Acutaas Chemicals Ltd
Glance View
Acutaas Chemicals Ltd. engages in the development and commercialization of pharmaceutical intermediate products and specialty chemicals. The company is headquartered in Surat, Gujarat. The company went IPO on 2021-09-14. The company is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. The company manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. The company has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Acutaas Chemicals Ltd is 23.6%, which is above its 3-year median of 12.9%.
Over the last 3 years, Acutaas Chemicals Ltd’s Net Margin has increased from 13.1% to 23.6%. During this period, it reached a low of 5% on Jun 30, 2024 and a high of 23.6% on Jan 1, 2026.
